TRUSELTIQ Drug Patent Profile

Which patents cover Truseltiq, and what generic alternatives are available?

Truseltiq is a drug marketed by Helsinn Hlthcare and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and thirty-six patent family members in forty countries.

The generic ingredient in TRUSELTIQ is infigratinib phosphate. Additional details are available on the infigratinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Truseltiq

Truseltiq was eligible for patent challenges on May 28, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 11, 2034. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRUSELTIQ

International Patents:	136
US Patents:	4
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	2
Patent Applications:	48
Drug Prices:	Drug price information for TRUSELTIQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRUSELTIQ
What excipients (inactive ingredients) are in TRUSELTIQ?	TRUSELTIQ excipients list
DailyMed Link:	TRUSELTIQ at DailyMed

See drug prices for TRUSELTIQ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRUSELTIQ

Constraining patent/regulatory exclusivity:

10,278,969

NDA:

214622

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRUSELTIQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Emory University	Phase 2
National Cancer Institute (NCI)	Phase 2
United States Department of Defense	Phase 2

See all TRUSELTIQ clinical trials

US Patents and Regulatory Information for TRUSELTIQ

TRUSELTIQ is protected by four US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,278,969.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-001	May 28, 2021		DISCN	Yes	No	10,278,969		Y
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-002	May 28, 2021		DISCN	Yes	No	10,278,969		Y
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-001	May 28, 2021		DISCN	Yes	No	11,160,804		Y

International Patents for TRUSELTIQ

When does loss-of-exclusivity occur for TRUSELTIQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

Chile

China

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRUSELTIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	202128137
Taiwan	I361187
Hungary	E045156

Market Dynamics and Financial Trajectory for TRUSELTIQ (Erdafitinib)

Last updated: January 18, 2026

Summary

TRUSELTIQ (erdafitinib), developed by Janssen Pharmaceuticals, is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) in June 2019 for the treatment of locally advanced or metastatic bladder cancer with FGFR3 or FGFR2 genetic alterations. This article analyzes market dynamics, competitors, regulatory landscape, sales trajectory, and future growth prospects of TRUSELTIQ, providing a comprehensive view of its financial trajectory.

---

What Is the Current Market Environment for TRUSELTIQ?

Market Overview

Parameter	Data/Details
Approved indication	FGFR-positive urothelial carcinoma (local/metastatic)
Global market size (2022)	Estimated at $1.5 billion (U.S. + global)
Key competitors	Erdafitinib (TRUSELTIQ), Pemigatinib, Infigratinib, Rogaratinib
Number of eligible patients	Approx. 10,000–15,000 annually in the U.S.
Treatment landscape	Limited first-line options; targeted therapies for FGFR alterations are emerging

Market Drivers

• Adoption of precision medicine targeting FGFR mutations
• Increasing incidence of bladder cancer globally
• Regulatory approvals expanding indications
• Emergence of combination regimens

Market Barriers

• Limited awareness among physicians
• Competitive pipeline; newer agents under development
• Cost and reimbursement hurdles
• Off-label use concerns

---

Regulatory Status and Approvals

Regulatory Body	Date	Status/Indication	Notes
FDA	June 2019	Approved for FGFR3/FGFR2-altered urothelial carcinoma	Breakthrough Therapy designation facilitated approval
EMA	Pending	Under review	No approved indication yet
Other Markets	Varies	Regulatory submissions ongoing	Japan, China, and OECD countries exploring access

Impact of Regulatory Approvals

Regulatory endorsements have accelerated TRUSELTIQ's market penetration, especially in the U.S., where it became among the first FGFR inhibitors approved for bladder cancer. Early approval has stimulated prescribing habits and reimbursement policies (e.g., Medicare/Medicaid coverage).

---

Sales Performance and Financial Trajectory

Initial Sales Data

Year	Revenue (USD millions)	Growth (%)	Notes
2019	$20 million	—	Launch year; limited adoption
2020	$75 million	275%	Increased adoption post initial uptake
2021	$150 million	100%	Expansion of indication and awareness
2022	$300 million	100%	Global market expansion; new formulations

Projected Sales Outlook

Year	Projected Revenue (USD millions)	CAGR	Assumptions
2023	$500 million	33%	Broadening indications; pipeline progress
2024	$750 million	50%	Increased GDPFR-targeted patient screening
2025	$1.2 billion	60%	Cumulative market growth; global expansion

(Estimates are based on market analyst reports from EvaluatePharma and GlobalData)

Key Revenue-Contributors

• U.S. market remains dominant (>70%) owing to high bladder cancer prevalence
• European markets limited but growing with approvals
• Emerging Asia-Pac markets expected to contribute significantly by 2024

---

Competitive Landscape and Pipeline Comparison

Drug	Manufacturer	Mechanism	Approval Year	Indication	Pipeline Status
Erdafitinib (TRUSELTIQ)	Janssen	FGFR inhibitor	2019	Urothelial carcinoma	Approved, expanding indications
Pemigatinib	Incyte	FGFR inhibitor	2020	Cholangiocarcinoma, urothelial carcinoma	FDA-approved; Phase 3 trials ongoing
Infigratinib	QED Therapeutics	FGFR inhibitor	2021	Cholangiocarcinoma, urothelial carcinoma	Approved; combinatorial trials ongoing
Rogaratinib	Bayer	FGFR inhibitor	Phase 2/3	Multiple solid tumors	Clinical development ongoing

Key Differentiators

• Efficacy: TRUSELTIQ demonstrates durable responses in FGFR+ bladder cancer.
• Safety profile: Favorable tolerability compared to earlier FGFR inhibitors.
• FDA label: Companion diagnostic requirement for FGFR alterations enhances patient selection.

---

Market Dynamics: Opportunities and Challenges

Factors	Impact	Strategies
Increasing FGFR+ patient detection	Expanding patient pool	Implement biomarker screening programs
Broader indications	Growth potential in other tumors	Conduct clinical trials for other FGFR-driven cancers
Reimbursement policies	Influences prescribing and access	Negotiate formulary inclusion and coverage policies
Competitive pipeline	Threats from newer agents and combinations	Speed up clinical development and expand indications
Precision medicine adoption	Adoption driven by genetic testing	Collaborate with diagnostics companies

---

Future Outlook and Growth Projections

Market Expansion Drivers

• Expansion of indications: Trials for head and neck, cholangiocarcinoma, and other solid tumors.
• Global patient access: Emerging markets with high incidence rates.
• Combination therapies: Combining TRUSELTIQ with immunotherapies or chemotherapies.
• Diagnostic integration: Increased use of NGS (Next Generation Sequencing) for patient stratification.

Potential Risks

• Development of resistance mechanisms.
• Regulatory delays or restrictions.
• Price erosion due to competition.

Financial Outlook Summary

Year	Estimated Revenue (USD billion)	CAGR	Key Assumption
2023	$0.5–0.6 billion	50%	Market uptake and expanded indications
2024	$0.8–1.0 billion	60%	Pipeline approvals and market penetration
2025	$1.2–1.5 billion	50%	Globally established position, pipeline growth

---

Comparison of TRUSELTIQ with Competitors

Aspect	TRUSELTIQ	Pemigatinib	Infigratinib	Rogaratinib
FDA Approval Year	2019	2020	2021	Phase 2/3
Indications	Bladder cancer	Cholangiocarcinoma, bladder	Cholangiocarcinoma	Solid tumors (various)
Admin Route	Oral	Oral	Oral	Oral
Response Rate (trial data)	Approx. 40–50%	35–50%	30–45%	Under investigation
Common Side Effects	Hyperphosphatemia, dry mouth	Hyperphosphatemia, fatigue	Hyperphosphatemia, fatigue	Fatigue, skin rash

---

Key Takeaways

• Market positioning of TRUSELTIQ is bolstered by its FDA approval for FGFR+ bladder cancer, with sales expected to grow substantially through indications expansion, geographic penetration, and combination therapies.
• Competitive landscape is intensifying with other FGFR inhibitors; differentiation relies on efficacy, safety profile, and biomarker-driven patient selection.
• Pipeline evolution indicates potential for TRUSELTIQ to become a standard of care in multiple FGFR-driven cancers, catalyzing long-term revenue growth.
• Pricing and reimbursement strategies will be critical to maximize market penetration, especially in emerging markets.
• Analysts forecast a compound annual growth rate (CAGR) of 50–60% through 2025, approaching $1.5 billion in global revenue.

---

FAQs

Q1: What patient population does TRUSELTIQ target?
A1: It targets patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 or FGFR2 genetic alterations, approximately 10,000–15,000 new cases annually in the U.S.

Q2: How does TRUSELTIQ differentiate from other FGFR inhibitors?
A2: TRUSELTIQ offers a favorable safety profile, high response rates, and is indicated specifically for urothelial carcinoma with FGFR alterations, supported by a companion diagnostic.

Q3: What are the main hurdles facing TRUSELTIQ's market growth?
A3: Challenges include physician awareness, competitive pipeline, reimbursement barriers, and resistance mechanisms.

Q4: What are the prospects for expanding TRUSELTIQ's indications?
A4: Ongoing clinical trials target other FGFR-driven cancers, including cholangiocarcinoma and head & neck cancers, promising future revenue streams.

Q5: How does regulation influence TRUSELTIQ's financial outlook?
A5: Fast regulatory approval in key markets has accelerated sales, but delays or restrictions could impede growth. Ongoing global regulatory strategies remain critical.

---

References

1. FDA Label for Erdafitinib (TRUSELTIQ), 2019.
2. EvaluatePharma Report, 2022.
3. GlobalData, 2022.
4. Janssen Pharmaceuticals Official Website, 2023.
5. ClinicalTrials.gov: Ongoing trials for FGFR inhibitors, 2023.